EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies
Sunshine Biopharma Inc. (NASDAQ: SBFM ) on Wednesday announced it advanced its lead Coronavirus drug candidate into IND-enabling studies. The company had previously published laboratory results on its library of compounds in August 2024 and more recently in March 2026. Background and Compound Research The company said